SuperworthCencora COR
- Market cap
- $63.2B
- PE
- 24.6×
- 10y median 21.1×
- Forward PE
- 17.0×
- 10y median 13.9×
- Price to sales
- 0.2×
- EV/EBIT
- 13.2×
- Revenue, 12 months
- $332.8B
- +5% on a year ago
- Net margin
- 0.8%
- Free cash flow yield
- 6.4%
Cencora trades at 24.6× trailing earnings, pricier than 70% of the last ten years. Revenue was $332.8B over the last twelve months, up 5% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $68.9B+13% | $72.3B+15% | $68.4B+8% | $74.2B+11% | $79.1B+15% | $81.5B+13% | $75.5B+10% | $80.7B+9% | $83.7B+6% | $85.9B+6% | $78.4B+4% | $84.8B+5% | |
| Cost of revenue | $66.7B+13% | $69.8B+15% | $65.9B+8% | $71.8B+11% | $76.6B+15% | $78.9B+13% | $72.4B+10% | $77.8B+8% | $80.8B+6% | $82.9B+5% | $74.8B+3% | $81.1B+4% |
| Gross profit | $2.3B+14% | $2.5B+15% | $2.5B+11% | $2.4B+7% | $2.5B+11% | $2.6B+4% | $3.1B+21% | $2.9B+21% | $3B+19% | $3.1B+20% | $3.6B+17% | $3.6B+24% |
| SG&A | $1.4B+10% | $1.4B+8% | $1.4B+5% | $1.4B+6% | $1.5B+7% | $1.5B+5% | $1.6B+15% | $1.7B+21% | $1.7B+17% | $1.8B+22% | $2B+24% | $2.1B+28% |
| $476.9M+5% | $822.9M+30% | $553.3M−1% | $672.5M+0% | $126.6M−73% | $706.3M−14% | $1B+87% | $867.7M+29% | $18.5M−85% | $760.4M+8% | $1.1B+10% | $1.1B+29% | |
| Interest expense | $60.9M+18% | $40.6M−12% | $64.1M+0% | $31.3M−46% | $21M−66% | $27.9M−31% | $104M+62% | $81.8M+161% | $77.8M+271% | $72.4M+159% | $140.5M+35% | $140.7M+72% |
| Pre-tax income | $446.4M+17% | $783.4M+32% | $467.1M−9% | $628.3M+3% | $125.2M−72% | $620.4M−21% | $928.7M+99% | $896.3M+43% | −$187M | $708.6M+14% | $2.1B+125% | $996.4M+11% |
| $97.4M+17% | $180.4M+54% | $45.9M−45% | $140.7M+9% | $117.7M+21% | $126.7M−30% | $211.2M+361% | $206.5M+47% | $146M+24% | $142.5M+13% | $459M+117% | $219.7M+6% | |
| Net income | $350.6M+19% | $601.5M+25% | $420.8M−3% | $483.5M+1% | $3.4M−99% | $488.6M−19% | $717.9M+71% | $687.4M+42% | −$339.7M | $559.6M+15% | $1.6B+129% | $763.5M+11% |
| $1.72+23% | $2.98+28% | $2.09−2% | $2.42+3% | $0.02−99% | $2.50−16% | $3.68+76% | $3.52+46% | −$1.75 | $2.87+15% | $8.40+128% | $3.94+12% | |
| 203.4M−3% | 201.8M−2% | 201.2M−2% | 200M−2% | 198.1M−3% | 195.2M−3% | 195.1M−3% | 195.2M−2% | 193.9M−2% | 195.3M+0% | 195.4M+0% | 193.9M−1% |
EPS, diluted: 10 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY08 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $88B | $87.9B to $88B | $4.58 | $4.47 to $4.61 | 6 |
| Q1 FY27 | $90B | $89.6B to $90.4B | $4.58 | $4.44 to $4.87 | 6 |
| Q2 FY27 | $82.2B | $81.6B to $82.6B | $5.28 | $5.24 to $5.32 | 2 |
| Q3 FY27 | $87.5B | $86.8B to $88B | $4.96 | $4.91 to $4.99 | 2 |
| Q4 FY27 | $90.8B | $90.1B to $91.3B | $5.03 | $4.99 to $5.07 | 2 |
| Q1 FY28 | $92.9B | $92.3B to $93.4B | $4.96 | $4.92 to $5.00 | 2 |
| Q2 FY28 | $84.7B | $84.1B to $85.1B | $5.54 | $5.49 to $5.58 | 5 |
| Q3 FY28 | $91.5B | $90.8B to $92B | $5.55 | $5.50 to $5.59 | 5 |
Peers
Companies in Medical - Distribution nearest Cencora's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CORCencora | $63.2B | 24.6× | 21.1× | 17.0× | 0.2× | +5% | 0.8% |
| CAHCardinal Health | $58B | 34.5× | 25.1× | 19.9× | 0.2× | +14% | 0.7% |
| MCKMcKesson | $116.7B | 26.8× | 24.7× | 21.6× | 0.3× | +9% | 1.1% |
| HSICHenry Schein | $9.5B | 24.8× | 21.2× | n/m | 0.7× | +6% | 3.0% |
| Peer median | $58B | 26.8× | 24.7× | 20.7× | 0.3× | +9% | 1.1% |
More on Cencora
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #8of 34Healthcare stocks with the lowest PEG ratio
- #3of 10Medical distribution stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Distribution
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .